ShanghaiA trial found an 81.5% response rate.
The trial recruited patients previously told they didn’t qualify for targeted therapy.
The China-developed antibody-drug conjugate targets a “HER2-low” category invisible to older tests.
Researchers say larger randomized trials are still needed before doctors can prescribe it routinely.
Sources: Nature